Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 7, July, p. 987–999

doi: 10.17219/acem/74437

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease

Ewelina Grywalska1,A,B,C,D,F, Małgorzata Bartkowiak-Emeryk1,C, Marcin Pasiarski2,3,B, Karolina Olszewska-Bożek1,B, Michał Mielnik1,B, Martyna Podgajna1,B, Monika Pieczykolan1,C, Anna Hymos4,B, Elżbieta Fitas1,B, Agata Surdacka1,C, Stanisław Góźdź3,5,E,F, Jacek Roliński1,E,F

1 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland

2 Department of Hematology, Holycross Cancer Center, Kielce, Poland

3 Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland

4 Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Poland

5 Department of Oncology, Holycross Cancer Center, Kielce, Poland


Background. Chronic lymphocytic leukemia (CLL) is a condition characterized by the accumulation of morphologically mature monoclonal lymphocytes B with the CD19+/CD5+/CD23+ phenotype in lymphoid tissue, peripheral blood and bone marrow. The clinical course of patients with CLL is heterogeneous, ranging from indolent to aggressive. The role of lymphocyte activation in the natural history of CLL is still a matter of discussion.
Objectives. The aim of this study was to determine the percentages and absolute numbers of lymphocytes B and T in peripheral blood and bone marrow of CLL patients. Moreover, we analyzed the relationship between the number of CD25-positive and CD69-positive lymphocytes and the established prognostic factors in CLL.
Material and Methods. The study included 80 untreated patients with CLL and 20 healthy subjects. The immunophenotype of peripheral blood mononuclear cells (in both groups) and bone marrow cells (solely in the CLL group) was determined by means of flow cytometry.
Results. Patients with CLL showed a higher absolute number of activated lymphocytes B with phenotypes CD19+CD25+ and CD19+CD69+, as well as a higher absolute number of CD3+CD25+ lymphocytes T than the controls. The enhanced activation of peripheral blood and bone marrow lymphocytes was associated with higher Rai stages, an increased concentration of lactate dehydrogenase and beta-2 microglobulin and the progression of the disease. The number of lymphocytes B CD19+ZAP-70+ correlated positively with the number of CD19+CD25+ B cells and CD3+CD69+ T cells.
Conclusion. The study confirmed the association between an unfavorable prognosis and a high expression of activation markers in CLL patients. The determination of CD25+ and CD69+ lymphocytes T and B constitutes a valuable diagnostic tool, completing the cytometric evaluation of CLL.

Key words

flow cytometry, chronic lymphocytic leukemia, prognostic marker, lymphocyte count

References (40)

  1. Linet M, Schubauer-Berigan M, Weisenburger D, et al. Chronic lymphocytic leukaemia: An overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol. 2007; 139(5):672–686. doi:10.1111/j.1365-2141.2007.06847.x
  2. Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol. 2002;116(2):341–345. doi:10.1046/j.0007-1048.2001.03286.x
  3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2): 219–234.
  4. Binet J, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.
  5. Klepfish A, Rachmilewitz E, Sarid M, Schattner A. Evaluating the impact of age and disease on survival of chronic lymphocytic leukaemia patients by a new method. Int J Clin Pract. 2009;63(11):1601–1603. doi:10.1111/j.1742-1241.2009.02008.x
  6. Amu S, Gjertsson I, Brisslert M. Functional characterization of murine CD25 expressing B cells. Scand J Immunol. 2010;71(4):275–282. doi:10. 1111/j.1365-3083.2010.02380.x
  7. Karp M, Kosior K, Karczmarczyk A, et al. Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells. Adv Clin Exp Med. 2015;24(1):55–62. doi:10.17219/acem/29264
  8. Pepper C, Majid A, Lin T, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol. 2012;156(4): 499–507. doi:10.1111/j.1365-2141.2011.08974.x
  9. Bazargan A, Tam C, Keating M. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12(3):393–403. doi:10.1586/era.12.2
  10. Wierda W, O’Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009;27(10):1637–1643. doi:10.1200/jco.2008.18.1701
  11. Rassenti L, Kipps T. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006;70(4): 209–213. doi:10.1002/cyto.b.20129
  12. Martinelli S, Cuneo A, Formigaro L, et al. Identifying high-risk chronic lymphocytic leukemia: A pathogenesis-oriented appraisal of prognostic and predictive factors in patients treated with chemotherapy with or without immunotherapy. Mediterr J Hematol Infect Dis. 2016; 8(1):e2016047. doi:10.4084/MJHID.2016.047
  13. Molica S, Shanafelt T, Giannarelli D, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016;91(11):1090–1095. doi:10.1002/ajh. 24493
  14. Karabon L, Partyka A, Jasek M, et al. Intragenic variations in BTLA gene influence mRNA expression of BTLA gene in chronic lymphocytic leukemia patients and confer susceptibility to chronic lymphocytic leukemia. Arch Immunol Ther Exp. 2016;64(S1):137–145. doi:10. 1007/s00005-016-0430-x
  15. Kubeczko M, Nowara E, Spychałowicz W, et al. Efficacy and safety of vitamin D supplementation in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2016;70:534–541. doi:10. 5604/17322693.1202482
  16. Grywalska E, Hymos A, Korona-Głowniak I, et al. Assessment of the influence of peripheral blood mononuclear cell stimulation with Streptococcus pneumoniae polysaccharides on expression of selected Toll-like receptors, activation markers and Fas antigen in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2016;70:959–967. doi:10.5604/17322693.1219399
  17. Chiorazzi N, Rai K, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804–815. doi:10.1056/nejmra041720
  18. Ziolkowska E, Wolowiec D, Cebula-Obrzut B, et al. Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. Postepy Hig Med Dosw (Online). 2014;68:1433–1443. doi:10.5604/17322693.1130704
  19. Andersen M, Vojdeman F, Andersen M, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592–1599. doi:10.3109/10428194.2016.1142082
  20. Tsai H, Caporaso N, Kyle R, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: A prospective study. Blood. 2009;114(24):4928–4932. doi:10.1182/blood-2009-08-237651
  21. Scrivener S, Goddard R, Kaminski E, Prentice A. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(3): 383–389. doi:10.1080/1042819021000029993
  22. De Fanis U, Romano C, Dalla Mora L, et al. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells. Oncol Rep. 2003;10(3): 653–658.
  23. Hassanein N, Perkinson K, Alcancia F, Goodman B, Weinberg J, Lagoo A. A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. Am J Clin Pathol. 2010;133(5):708–717. doi:10.1309/ajcpqs4oxjjsz5kn
  24. Rossmann E, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol. 2002;68(5):299–306. doi:10. 1034/j.1600-0609.2002.01612.x
  25. Damle R, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99(11):4087–4093. doi:10.1182/blood.v99.11.4087
  26. Seifert M, Küppers R. Human memory B cells. Leukemia. 2016;30(12): 2283–2292. doi:10.1038/leu.2016.226
  27. Rosenwald A, Alizadeh A, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639–1648. doi:10.1084/jem.194.11.1639
  28. Shvidel L, Braester A, Bairey O, et al. Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: Results of a retrospective study of 281 patients. Ann Hematol. 2012;91(10):1597–1602. doi:10.1007/s00277-012-1492-4
  29. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22(4):211–219. doi:10.1016/j.blre.2008. 03.003
  30. Rivkina A, Holodnuka-Kholodyuk I, Murovska M, Soloveichika M, Lejniece S. Peripheral blood lymphocyte phenotype of ZAP-70(+) and ZAP-70(−) patients with B-cell chronic lymphocytic leukaemia. Exp Oncol. 2015;37(1):73–76.
  31. Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol. 2002;68(3):127–134. doi:10.1034/j.1600-0609.2002.01515.x
  32. Ma ES. Recurrent cytogenetic abnormalities in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Methods Mol Biol. 2017; 1541:279–293. doi:10.1007/978-1-4939-6703-2_22
  33. Amaya-Chanaga C, Rassenti L. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016;29(1):79–89. doi:10.1016/j.beha.2016.08.005
  34. Rawstron A, Shingles J, de Tute R, Bennett F, Jack A, Hillmen P. Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. Cytometry B Clin Cytom. 2010;78(S1):S42–S46. doi:10.1002/cyto.b.20534
  35. Martkamchan S, Onlamoon N, Wang S, Pattanapanyasat K, Ammaranond P. The effects of anti-CD3/CD28 coated beads and IL-2 on expanded T cell for immunotherapy. Adv Clin Exp Med. 2016;25(5):821–828. doi:10.17219/acem/35771
  36. Zuśka-Prot M, Jaroszewski J, Maślanka T. Involvement of regulatory T cells and selected cytokines in the pathogenesis of bronchial asthma. Postepy Hig Med Dosw (Online). 2016;70:668–677. doi:10.5604/ 17322693.1207511
  37. Wotherspoon A, Attygalle A, Mendes LS. Bone marrow and splenic histology in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015; 28(4):200–207. doi:10.1016/j.beha.2015.10.019
  38. Janik J. Tumor markers in hairy cell leukemia. Leuk Lymphoma. 2011; 52(Suppl 2):69–71. doi:10.3109/10428194.2011.568651
  39. Nakase K, Kita K, Miwa H, et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: Interleukin-2 receptor α-chain predicts a poor prognosis. Leukemia. 2007;21(2):326–332. doi:10.1038/sj.leu.2404497
  40. Oki Y, Kato H, Matsuo K, et al. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma. 2008;49(7):1345–1351. doi:10.1080/10428190802108888